Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate Non-Small-cell Lung Cancers in Vivo

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Enhanced Antiproliferative and Apoptosis Effect of Paclitaxel-Loaded Polymeric Micelles Against Non-Small Cell Lung Cancers

<sub>3</sub><sub>1</sub> Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment

Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression.

Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugate in Resistant Lung Cancer

Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles

Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment.

Overcoming Drug-Resistant Lung Cancer by Paclitaxel Loaded Tetrahedral DNA Nanostructures.

PD-L1-targeted Microbubbles Loaded with Docetaxel Produce a Synergistic Effect for the Treatment of Lung Cancer under Ultrasound Irradiation

Improving Drug Delivery of Micellar Paclitaxel against Non-Small Cell Lung Cancer by Coloading Itraconazole as a Micelle Stabilizer and a Tumor Vascular Manipulator.

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals

Β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy As Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.

Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Chrysin-functionalized gold nanoparticles and paclitaxel exhibit synergistic impact on lung cancer cell lines via regulating the AKT/PPAR-ϒ/β-catenin pathway

Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy

Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer

Liposome-based Co-Delivery of Sirna and Docetaxel for the Synergistic Treatment of Lung Cancer.

Paclitaxel-loaded poly(Glycolide-co-εcaprolactone)-b-d-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy